Biotie: Notification according to Chapter 9, Section 10 of the Finnish Securities Market Act

(Thomson Reuters ONE) -


BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 14 November 2013 at 3.30 pm.

Notification according to Chapter 9, Section 10 of the Finnish Securities Market
Act

Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of a
notification regarding changes in number of votes in accordance with Chapter 9,
Section 5 of the Finnish Securities Markets Act, described below.

The notification received by the Company concerns the changes in holdings of the
Company's shares by Novo A/S as a result of the transactions carried out on 13
November 2013. As a result of these transactions, the aggregate holding of Novo
A/S has decreased below 5 per cent of the total number of shares and votes of
the Company.

The change in holdings in accordance with Chapter 9, Section 5 of the Finnish
Securities Markets Act of which the Company has gained knowledge of is described
below:

Name Number of shares Number of shares (%) of shares (%) of voting
and voting rights and voting rights after  rights after
before after

Novo A/S 26,141,552 17,441,554 3.85% 3.91%


The registered number of shares in Biotie Therapies Corp. is 452,710,738. Of
these shares 6,509,351 are held by the Company and the number of outstanding
shares and voting rights attached to the shares amounts thus to 446,201,387.

Turku, 14 November 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information please contact:

David Cook
CFO
email: david.cook(at)biotie.com

Tel: +358 2 2748 900

Virve Nurmi
Investor Relations Manager
email: virve.nurmi(at)biotie.com

Tel: +358 2 2748 911

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Biotie Therapies Oyj via Thomson Reuters ONE
[HUG#1743250]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 14.11.2013 - 14:30 Uhr
Sprache: Deutsch
News-ID 316700
Anzahl Zeichen: 2619

contact information:
Town:

Turku

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 143 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Biotie: Notification according to Chapter 9, Section 10 of the Finnish Securities Market Act"
steht unter der journalistisch-redaktionellen Verantwortung von

Biotie Therapies Oyj (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dep ...

TURKU, FINLAND -- (Marketwired) -- 05/10/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 10 May 2013 at 9.00 a.m.Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The Nat ...

Biotie: Selincro Launched in the United Kingdom ...

TURKU, FINLAND -- (Marketwired) -- 05/06/13 -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, B ...

Biotie: Selincro Launched in First European Markets ...

TURKU, FINLAND -- (Marketwired) -- 04/22/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 22 April 2013 at 9:00 a.m.Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has started launching Selincro™ in the first European markets, ...

Alle Meldungen von Biotie Therapies Oyj